The facts
The FDA's Center for Drug Evaluation and Research sent Warning Letter 320-27-02, dated October 1, 2026, via UPS and email to Maria C. Esparza, President and CEO of Signature Formulations LLC, 5446 W Rosevelt St. Suite 101, Phoenix, AZ 85043 (the letter spells it "Rosevelt"), maria@sigform.com.
Following a violative inspection, the FDA procured lots of the firm's contract-manufactured drug products and ran laboratory analysis. The FDA's analysis showed all sampled lots had contamination from shared-equipment cross-contamination. The products were "grossly contaminated" with undeclared substances and are adulterated under section 501(a)(2)(B) of the FD&C Act because the firm's methods do not conform to Current Good Manufacturing Practices, and under 501(a)(2)(A) because they were prepared under insanitary conditions.
"These contaminated drug products have the potential for serious adverse health consequences." The known harmful effects of exposure "may not appear for months or years after exposure and are not readily detectable by consumers."
On September 15, 2026, the FDA held a teleconference with the firm and recommended that it voluntarily recall all drug products in U.S. distribution. The firm "verbally committed to halt manufacturing and distribution as well as perform a voluntary recall of all" its drug products.
This is the second letter. Warning Letter 320-26-38, issued January 21, 2026, documented CGMP violations including cross-contamination risks, and a regulatory meeting on July 16, 2024 covered the same risks. In 2025 the firm recalled one lot for the same contamination. The new letter states: "It is unacceptable that you have had repeated instances of" contamination.
The firm manufactured its products "in the same manufacturing environment using shared equipment." The letter notes that to avoid cross contamination, companies "dedicate equipment, dedicate HVAC, and utilize other separation provisions (e.g., dedicated production suites, airlocks)", and that residues on shared surfaces "will not be adequately removed under standard cleaning conditions."
The FDA's analysis found "contamination across all sampled lots", and the letter concludes the findings "indicate a systemic failure that cannot be resolved through retrospective testing." "Contamination is nonuniformly distributed throughout all lots, the full extent of contamination across your firm's marketed drug products is unknown".
The FDA strongly advised the firm to retain a qualified consultant and warned of seizure, injunction, withheld approvals, and re-inspection. The firm has fifteen business days to respond.
Our take
Let's get this straight. Maria C. Esparza, President and CEO of Signature Formulations LLC, is a fucking menace. Her company takes money from other firms to manufacture their drugs, and for two goddamn years she has been pumping out contaminated garbage. The FDA held her hand in July 2024 and explained the basic concept of not mixing shit together. She did a one-lot recall in 2025 like she was taking out the trash. They sent her a formal warning letter in January 2026 saying, hey cunt, stop it. And now, in October, their lab tests show every single lot they sampled is still fucking contaminated. This isn't a regulatory process; it's begging a toddler not to eat paint after you've already scraped it out of their mouth twice.
The most pathetic detail in this whole shitshow is that her grand plan to fix it was a verbal commitment. After a teleconference on September 15, where the FDA told her to recall every goddamn pill in the country, Maria Esparza verbally committed to doing it. Verbally. The woman whose factory is such a biohazard that the FDA officially calls its conditions "insanitary" gave a fucking pinky swear over the phone. She couldn't dedicate a mop bucket, but she dedicated her word. What a brave, bold stance from a CEO whose entire business model is apparently hoping the government won't check.
And let's not skip the beautiful, petty poetry of the address on the warning letter: 5446 W Rosevelt St. Roosevelt is misspelled. Whether it's the FDA's typo or her company's own sloppy paperwork, it's perfect. It's the official mailing address for a operation so fundamentally lazy that checking the spelling of the street is apparently as big an ask as cleaning the equipment. When the regulator sending the 'you're poisoning people' notice can't even be arsed to spell it right, you know you're dealing with a special kind of institutionalized bullshit. The contamination is 'nonuniformly distributed,' which is bureaucrat for 'we have no fucking clue where the poison is, but it's everywhere.'
The FDA's letter says this is a 'systemic failure that cannot be resolved through retrospective testing.' No shit. The system is that Maria Esparza is a cheap, reckless prick who has been told repeatedly that her factory is a petri dish and who has done precisely fuck-all about it beyond mouthing words into a phone. The FDA is now threatening seizure and injunction, which is what they should have done after the first warning letter. Instead, they're giving her fifteen more business days to explain why she shouldn't be shut down for good. Here's a free response: because I'm a greedy asshole who thought I could get away with it, and you fuckers let me.
